CARLSON DNA Sequencing
Past New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $25,000 to $250,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Points of contact
-
- CBER Acquisition Liaison cbersacquisitions@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration is forecasting a new requirement for CARLSON DNA Sequencing, a microbiome sequencing service contract. This procurement falls under biotechnology research and development services and carries no set-aside designation. The solicitation is estimated to be released on December 1, 2025, with an anticipated contract award by February 1, 2026.
The estimated award value ranges from $25,000 to $250,000 for this biotechnology services contract. Interested contractors should direct inquiries to the FDA's Center for Biologics Evaluation and Research (CBER) Acquisitions team at cbersacquisitions@fda.hhs.gov. Companies meeting the NAICS code 541714 classification for research and development in biotechnology are encouraged to monitor this opportunity.
Forecast text
CARLSON DNA Sequencing. Microbiome sequencing service.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast